OptimizeRx Corporation Third Quarter 2026 Conference Call - OPTIMIZERX CORP

Explicit Guidance:

• FY2026 Revenue: Updated to $87 million – $93 million (previously higher), reflecting contracted revenue tracking ~20% below prior year levels and timing of customer spending decisions.
• FY2026 Adjusted EBITDA: Maintained at $21 million – $25 million.
• FY2026 Gross Margin: Expected to remain in the low 70% range for the full year, driven by margin optimization and cost management initiatives.
• FY2027 Revenue Outlook: Not providing specific numerical guidance yet; however, contracted revenue for 2027 is currently tracking ~20% ahead year-over-year, with growth rates anticipated to align closer to 2025 levels rather than 2026 declines.
• Q4 2026 Revenue Risk: Management notes "execution risk" regarding the conversion of the remaining revenue required to achieve the updated full-year range, noting a "lower" probability of upside surprise compared to prior quarters due to limited visibility into "buy-ups" (ad-hoc spending).
• Debt Reduction: No specific numerical target, but commitment to continue paying down outstanding loan principal ahead of schedule in combination with executing a share repurchase program.
• Share Repurchases: Intention to increase focus on stock buybacks, with expectations of "more activity" starting in Q4 2026.

Business-Segment Outlook:

• Customer Cohorts: Anticipated "outsized investment" and double-digit growth from mid-tier and long-tail clients, who are seen as leveling the playing field against top-tier pharma budgets; one mid-tier client has already moved into the "top 10" pool.
• Top Client Recovery: A previously displaced top-five client has returned in Q4 2026, generating revenue (though at non-historical levels) on non-budgeted dollars, expected to contribute to 2027 growth.
• Product Portfolio: Expansion of the Natural Language Audience Builder (NLAB) to include privacy-safe direct-to-consumer (DTC) audiences alongside HCP audiences, aiming to improve omni-channel planning efficiency.
• New Solutions: Introduction and scaling of the COPEQ solution and DAP (Demand Side Platform) integrations to support audience intelligence and media planning.
• Programmatic Revenue: Expectation that inventory will become available to PulsePoint advertisers throughout November 2026, contributing ~250,000 incremental New Patient Impressions (NPIs) to the network.

Market and Competitive Outlook:

• Industry Demand: Identification of pent-up demand among pharmaceutical manufacturers due to budget scrutiny and uncertainty regarding government policy (MFN pricing, election impacts), leading to delayed Q3/Q4 decisions but anticipated Q4/Q1 spend normalization.
• Competitive Positioning: OptimizeRx positioned as the only tech company with a proprietary, AI-enabled operating system across EHR systems; barriers to entry cited as the scale of the 1.1 million verified HCPs across 450+ EHR systems and the difficulty of replicating proprietary data assets.
• Programmatic Adoption: Anticipated shift toward integrating point-of-care advertising into broader omni-channel strategies via leading Demand Side Platforms (DSPs), specifically expecting to capture a greater share of marketing budgets through DeepIntent, The Trade Desk, and PulsePoint (representing ~60-70% of volume in the programmatic space).
• Growth Drivers: Expectation of improved Net Revenue Retention (NRR) in 2027 as the one-time disruption from the major client is normalized, potentially returning NRR to >100%.

Macro / Industry Outlook:

• Pharma Spending Environment: Acknowledgement of "evolving spending priorities," "budget scrutiny," and "heightened focus on measurable returns." Clients are "warehousing" dollars and delaying decisions pending clarity on political and regulatory landscapes.
• Regulatory/Political Impact: Clients express uncertainty regarding the shift from a Republican to a Democratic administration; anticipated impacts include potential "pinata stick" effects via MFN (Most Favored Nation) pricing and drug policy changes, leading to recalibration of 2027 budgets.
• Customer Sentiment: Management reports the internal business "mojo" and sentiment are at their best in a long time, with strong momentum in the 2027 RFP season.

Strategic Initiatives:

• AI & Technology: Continued investment in AI-enabled platform capabilities (DAP, NLAB) designed to scale without proportional cost increases, anticipating "recurring revenue opportunities" and improved customer retention.
• Commercial Organization: Strengthening the go-to-market strategy with the addition of Sarah Bass (Chief Marketing Officer) in Q3 2026 to deepen relationships with manufacturers and agencies.
• Leadership Transition: Ed Stelmach (CFO/Strategy) transitioning to Strategic Advisor at end of 2026; Andy DeSilva to assume CFO role effective January 1, 2027, and Heather Favazza to become Chief Accounting Officer.
• Partnerships: Expansion of programmatic distribution via integrations with DeepIntent, The Trade Desk, and PulsePoint to eliminate barriers to entry for advertisers using authenticated clinical inventory.
• Cost Structure: Ongoing optimization of OpEx and fixed costs, with a goal to achieve >30% EBITDA margins as revenue growth returns, leveraging the scalable operating model.

Risks and Headwinds to Outlook:

• Revenue Recognition Timing: High risk that the $87–$93M FY2026 revenue target will not be met if "buy-up" activity (ad-hoc spending) does not materialize in the final six weeks of 2026 due to lack of visibility.
• Customer Concentration: Continued reliance on a limited number of large customers; the 20% contracted revenue shortfall was significantly driven by one major client's spending pause (representing ~10 points of NRR decline).
• Policy Uncertainty: Potential headwinds from government regulation, drug pricing policies (MFN), and the "frothy" vs. "recalibrated" spending environment resulting from political shifts.
• Execution Risk: Dependence on the 2027 RFP season performance and the speed of converting pipeline opportunities into signed agreements and recognized revenue.
• Competitive/Technical Risks: Risks related to maintaining contracts with EHR networks, cybersecurity incidents, and the ability to keep pace with evolving AI and programmatic technologies.

Management Tone on the Future:

• Confidence Level: Cautiously optimistic regarding long-term prospects and 2027 growth, describing 2027 projections as "looking a little bit more like growth rates from 2025."
• Hedges: Explicitly states "no obligation to update guidance" and emphasizes transparency over "rolling the dice" on upside, acknowledging the "execution risk" in Q4 2026.
• Strategic Shift: Tone indicates a pivot from "top-line growth at all costs" to "disciplined, profitable growth," with a renewed focus on converting existing pipeline and scaling the programmatic business model.
• Sentiment: Leadership expresses strong confidence in the "differentiated" competitive advantages (AI, proprietary data, EHR network) and believes the current spending dip is temporary and driven by external macro factors rather than lack of product demand.

Miscellaneous:

• Cash Position: Ended Q3 2026 with $22.3 million in cash; subsequent to quarter-end, paid an additional $3 million in debt, reducing outstanding balance to $10.4 million.
• Operating Cash Flow: $12.9 million for the first nine months of 2026.
• Debt Structure: Refinanced long-term loan with Fifth Third Bank ($25M term at SOFR + 2.25% + $10M revolver); currently ahead of payment schedule.
• KPIs: Average revenue per top 20 manufacturer is $2.5 million; Revenue per FTE is $706,000.